OpenVSafe by OpenVAERS
Search V-safe

EQJ-30920-99549

1 vaccination 5 coded responses 13 check-ins 5 free-text entries 3 call cases
Sex
Female
Age at first dose
66+
ZIP prefix
850 / AZ
Registered
2021-04-07
Relationship
Self
Race
White
Ethnicity
Not Hispanic or Latino

Timeline

  1. 2021-04-06
    Dose 1 — Pfizer-BioNTech
  2. 2021-04-07
    Registered in v-safe
  3. 2021-04-07
    Health check-in — days 1–6 daily, dose 1
    Feeling: Fair · Site: Pain · None
    Adult check-in
  4. 2021-04-08
    Survey response — days 1–6 daily, dose 1
    MedDRA: Arthritis, Cystitis interstitial, Fibromyalgia — Feeling: Fair · Site: Pain · Fever · Headache, Joint pains, Muscle or body aches, Fatigue or tiredness, Rash, not including the immediate area around the injection site · Be unable to do your normal daily activities
    Free text: Primarily exacerbation of existing arthritis, fibromyalgia and interstitial cystitis
    MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
  5. 2021-04-09
    Health check-in — days 1–6 daily, dose 1
    Feeling: Fair · Fatigue or tiredness, Rash, not including the immediate area around the injection site · Be unable to do your normal daily activities
    Adult check-in
  6. 2021-04-10
    Health check-in — days 1–6 daily, dose 1
    Feeling: Poor · Fatigue or tiredness, Rash, not including the immediate area around the injection site · Be unable to do your normal daily activities
    Adult check-in
  7. 2021-04-11
    Health check-in — days 1–6 daily, dose 1
    Feeling: Fair · Fatigue or tiredness, Rash, not including the immediate area around the injection site · Be unable to do your normal daily activities
    Adult check-in
  8. 2021-04-20
    Survey response — day 14, dose 1
    MedDRA: Immunisation reaction, Rash — Feeling: Fair · Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visit
    Free text: Severe rash, needing urgent care visit. This started soon after vaccine administered. Have been advised to consider skipping dose #2.
    MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
  9. 2021-04-20
    Report sent to call center — day 14, dose 1
    Be unable to do your normal daily activities · Get care from a doctor or other healthcare professional
    1 call case(s)
  10. 2021-04-27
    Survey response — day 21, dose 1
    MedDRA: Injection site induration, Injection site pain, Office visit, Rash, Sleep disorder — Feeling: Poor · Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visit
    Free text: Symptoms: Severe rash over multiple areas of body, including throat and eye. Arm where injection applied painful and stiff. Sleep interrupted by itching. PCP said not to get 2nd dose. · Healthcare visit (other): 2nd visit was to PCP in office.
    MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
  11. 2021-04-27
    Report sent to call center — day 21, dose 1
    Be unable to do your normal daily activities · Get care from a doctor or other healthcare professional
    1 call case(s)
  12. 2021-05-04
    Survey response — day 28, dose 1
    MedDRA: Office visit, Rash, Visual impairment — Feeling: Poor · Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visit
    Free text: Symptoms: Severe rash now threatening eyesight. Have seen: urgent care, PCP, and will see allergist tomorrow. · Healthcare visit (other): PCP seen, referred to allergist
    MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
  13. 2021-05-04
    Report sent to call center — day 28, dose 1
    Be unable to do your normal daily activities · Get care from a doctor or other healthcare professional
    1 call case(s)
  14. 2021-05-11
    Health check-in — day 35, dose 1
    Feeling: Poor
    Adult check-in
  15. 2021-05-18
    Health check-in — day 42, dose 1
    Feeling: Poor
    Adult check-in
  16. 2021-07-06
    Health check-in — 3 months, dose 1
    Feeling: Fair
    Adult check-in
  17. 2021-10-05
    Survey response — 6 months, dose 1
    MedDRA: Hypersensitivity, Rash — Feeling: Poor · Be unable to do your normal daily activities
    Free text: The rash accompanying my allergic reaction has returned.
    MedDRA releases: 2024-11 · check-in free text available
  18. 2022-04-01
  19. 2022-04-06
    Health check-in — 12 months, dose 1
    Feeling: Fair
    Adult check-in

Vaccinations

DoseDateManufacturerCo-administered
12021-04-06Pfizer-BioNTech

Call center

3 call center cases

3 unsuccessful

1 wait over 3 months for a first call

See the call center timeline

Free text

Release 7 — days 1–6 daily, dose 1

2021-04-08

Systemic reaction (other): Primarily exacerbation of existing arthritis, fibromyalgia and interstitial cystitis

Release 7 — day 14, dose 1

2021-04-20

Symptoms: Severe rash, needing urgent care visit. This started soon after vaccine administered. Have been advised to consider skipping dose #2.

Release 8 — day 21, dose 1

2021-04-27

Symptoms: Severe rash over multiple areas of body, including throat and eye. Arm where injection applied painful and stiff. Sleep interrupted by itching. PCP said not to get 2nd dose.
Healthcare visit (other): 2nd visit was to PCP in office.

Release 8 — day 28, dose 1

2021-05-04

Symptoms: Severe rash now threatening eyesight. Have seen: urgent care, PCP, and will see allergist tomorrow.
Healthcare visit (other): PCP seen, referred to allergist

Release 10 — 6 months, dose 1

2021-10-05

Symptoms: The rash accompanying my allergic reaction has returned.

Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".

MedDRA terms by release

FieldPreferred term2021-092023-042024-11
HCVOOffice visit ✓ ✓ ✓
SDHypersensitivity · · ✓
SDImmunisation reaction ✓ ✓ ✓
SDInjection site induration ✓ ✓ ✓
SDInjection site pain ✓ ✓ ✓
SDOffice visit ✓ ✓ ✓
SDRash ✓ ✓ ✓
SDSleep disorder ✓ ✓ ✓
SDVisual impairment ✓ ✓ ✓
SROArthritis ✓ ✓ ✓
SROCystitis interstitial ✓ ✓ ✓
SROFibromyalgia ✓ ✓ ✓

✓ active code · ○ coded but marked inactive · blank = not in that release